GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Lofexidine - LUCEMYRA

Local official-label summaryBase record retrieved 2026-09-08See the evidence for this drug2 sources available - open source summaries, references and comparisons

LUCEMYRA / Lofexidine

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
LUCEMYRA: a renal table does not cancel the chronic-renal-failure warning

The retrieved 2026 official label retains both a renal dosage table and an avoid-use warning for chronic renal failure. This is an unresolved within-label applicability tension, not evidence that either passage can be discarded.

Before applying: Do not use the table as automatic eligibility. Review the full warning, vital signs, ECG and specialist assessment; the RX mirror is not independent corroboration.

Also check: LUCEMYRA: a renal table does not cancel the chronic-renal-failure warning

Official source

Lofexidine - LUCEMYRA official label

Product / population
Lofexidine - LUCEMYRA official label; selected renal source sections only, not a complete prescribing monograph.
Renal measure
eGFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.

Exact DailyMed result selected by product and packager. Newer label retains the table/warning tension; it is not independently adjudicated here.

Renal dosing, restrictions and evidence limits

The renal table gives two 0.18-mg tablets four times daily (1.44 mg/day) at eGFR 30-89.9 mL/min/1.73 m2, and one tablet four times daily (0.72 mg/day) below 30, including ESRD or dialysis. Timing need not follow dialysis. However, the same label warns to avoid use in chronic renal failure. Do not treat the table as automatic eligibility. Monitor vital signs, bradycardia and orthostasis; renal impairment also warrants ECG assessment. Taper rather than stop abruptly.

Source revision: Prescribing information revised 4/2026. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a848cc2-4dda-40d9-8b01-d789fe8981ed

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Lofexidine - LUCEMYRA official label

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Lofexidine - LUCEMYRA official label; selected renal source sections only, not a complete prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.
Retrieved: 2026-09-08

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - LUCEMYRA

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Lofexidine - LUCEMYRA; selected renal source sections only, not a complete prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

LUCEMYRA: a renal table does not cancel the chronic-renal-failure warning

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

guideline difference

LUCEMYRA: a renal table does not cancel the chronic-renal-failure warning

The retrieved 2026 official label retains both a renal dosage table and an avoid-use warning for chronic renal failure. This is an unresolved within-label applicability tension, not evidence that either passage can be discarded.

How to use this: Do not use the table as automatic eligibility. Review the full warning, vital signs, ECG and specialist assessment; the RX mirror is not independent corroboration.

GlobalRPh RX List - LUCEMYRALofexidine - LUCEMYRA official label

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeLofexidine - LUCEMYRA official labelGlobalRPh RX List - LUCEMYRA
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/lucemyra-drug/

Exact product and population

Lofexidine - LUCEMYRA; selected renal source sections only, not a complete prescribing monograph.

RDM47-SCOPE-lofexidine-lucemyra · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Lofexidine - LUCEMYRA official label

Open original reference

Open / share this exact local source

DailyMed / BioCorRx Pharmaceuticals Inc · Lofexidine - LUCEMYRA official label; selected renal source sections only, not a complete prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.
Source date: Prescribing information revised 4/2026.
Retrieved: 2026-09-08

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The renal table gives two 0.18-mg tablets four times daily (1.44 mg/day) at eGFR 30-89.9 mL/min/1.73 m2, and one tablet four times daily (0.72 mg/day) below 30, including ESRD or dialysis. Timing need not follow dialysis. However, the same label warns to avoid use in chronic renal failure. Do not treat the table as automatic eligibility. Monitor vital signs, bradycardia and orthostasis; renal impairment also warrants ECG assessment. Taper rather than stop abruptly.

RDM47-official-lofexidine-lucemyra-44a5cf3f0d-C1 · Source locator: Sections 2.3 Table 2, 5.1 and 5.2; lines 321-358.

Source-specific limits

Exact DailyMed result selected by product and packager. Newer label retains the table/warning tension; it is not independently adjudicated here.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a848cc2-4dda-40d9-8b01-d789fe8981ed
Retrieved
2026-09-08
Exact label title
Lofexidine - LUCEMYRA official label
DailyMed Set ID
0a848cc2-4dda-40d9-8b01-d789fe8981ed
Labeler
BioCorRx Pharmaceuticals Inc
DailyMed page updated
2026-07-22
Label revision
Prescribing information revised 4/2026.
Renal-function method
eGFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.
Source date/version
Prescribing information revised 4/2026.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
75b1283dc228eb42daef9d4a17866ac73e9da245269e14e026704a3a40eb1058
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - LUCEMYRA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Lofexidine - LUCEMYRA; selected renal source sections only, not a complete prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.
Source date: RX page prints September 2020.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The renal table gives two 0.18-mg tablets four times daily (1.44 mg/day) at eGFR 30-89.9 mL/min/1.73 m2, and one tablet four times daily (0.72 mg/day) below 30, including ESRD or dialysis. Timing need not follow dialysis. However, the same label warns to avoid use in chronic renal failure. Do not treat the table as automatic eligibility. Monitor vital signs, bradycardia and orthostasis; renal impairment also warrants ECG assessment. Taper rather than stop abruptly.

RDM47-rxlist-lofexidine-lucemyra-3977ab5ef1-C1 · Source locator: Renal dosage table, lines 44-56; warnings 5.1 and 5.2, lines 149-176.

Source-specific limits

The source names its 30-89.9 band moderate impairment. This is retained as a label-specific category, not adopted as general CKD staging.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/lucemyra-drug/
Retrieved
2026-09-08
Renal-function method
eGFR, mL/min/1.73 m2. Preserve the body-surface-area denominator.
Source date/version
RX page prints September 2020.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
75b1283dc228eb42daef9d4a17866ac73e9da245269e14e026704a3a40eb1058

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/lucemyra-drug/
Source retrieval
2026-09-08. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
afe477dff315e78d152a108d2c148ae54e9488e04d2527204071098d416d79a9
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report